Analyst Ratings For Inovio Pharmaceuticals (NASDAQ:INO)
Today, Maxim Group reiterated its Buy rating on Inovio Pharmaceuticals (NASDAQ:INO) with a price target of $8.00.
Some recent analyst ratings include
- 2/15/2018-Maxim Group Reiterated Rating of Buy .
- 10/18/2017-Royal Bank of Canada initiated coverage with a Outperform rating.
- 10/6/2017-Citigroup initiated coverage with a Buy rating.
- 7/18/2017-Aegis Reiterated Rating of Buy.
- 6/8/2017-Piper Jaffray Companies Upgrade from a “Neutral ” rating to a ” Overweight” rating.
- 5/25/2017-Stifel Nicolaus Reiterated Rating of Buy.
Recent Insider Trading Activity For Inovio Pharmaceuticals (NASDAQ:INO)
Inovio Pharmaceuticals (NASDAQ:INO) has insider ownership of 10.60% and institutional ownership of 32.04%.
- On 5/25/2017 David B Weiner, Director, sold 8,000 with an average share price of $8.00 per share and the total transaction amounting to $64,000.00.
- On 3/31/2017 Jong Joseph Kim, CEO, sold 147,180 with an average share price of $6.54 per share and the total transaction amounting to $962,557.20.
- On 3/27/2017 Morton Collins, Director, bought 21,300 with an average share price of $6.25 per share and the total transaction amounting to $133,125.00.
- On 8/29/2016 Niranjan Sardesai, COO, sold 21,800 with an average share price of $9.30 per share and the total transaction amounting to $202,740.00.
- On 6/28/2016 Morton Collins, Director, bought 10,000 with an average share price of $9.13 per share and the total transaction amounting to $91,300.00.
- On 5/18/2016 Simon X Benito, Director, sold 6,250 with an average share price of $10.37 per share and the total transaction amounting to $64,812.50.
- On 4/15/2016 Morton Collins, Director, bought 68,400 with an average share price of $9.52 per share and the total transaction amounting to $651,168.00.
Recent Trading Activity for Inovio Pharmaceuticals (NASDAQ:INO)
Shares of Inovio Pharmaceuticals closed the previous trading session at 4.13 down -0.05 1.20% with 4.190000057220459 shares trading hands.
